Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 07:27:54 18/06/2024 pm IST			5-day change	1st Jan Change
64.12 ^USD	-0.23%		-1.22%	-20.87%

14/06	Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	DJ
14/06	EU regulator mandates label updates on CAR-T cancer therapies	RE

EU regulator mandates label updates on CAR-T cancer therapies

June 14, 2024 at 08:15 pm IST

June 14 (Reuters) - The European health regulator said on Friday product information for a class of cancer therapies known as CAR-T treatments would be required to highlight risk of secondary cancers in patients who use them, ending a five-month safety review. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
JOHNSON & JOHNSON	145.9 USD	-0.05%	-0.34%	351B
NOVARTIS AG	93.12 CHF	-0.45%	-0.85%	214B
GILEAD SCIENCES, INC.	64.12 USD	-0.23%	-1.22%	80.07B

Latest news about Gilead Sciences, Inc.

Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	15/06	DJ
EU regulator mandates label updates on CAR-T cancer therapies	14/06	RE
Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta	14/06	MT
Kite Announces Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit From Earlier Lines of Treatment	14/06	CI
Transcript : Gilead Sciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM	12/06
Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer	10/06	MT
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA	06/06	MT
Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study	06/06	CI
Transcript : Gilead Sciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM	05/06
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial	05/06	MT
Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis, A Rare, Chronic Inflammatory Liver Disease	05/06	CI
Sector Update: Health Care Stocks Rise Late Afternoon	05/06	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	04/06	MT
Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit	04/06	MT
Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma	03/06	MT
Kite?S Tecartus® Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia	03/06	CI
Kite Announces Data from A Pilot Study in Collaboration with Dana-Farber Cancer Institute	03/06	CI
Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise	03/06	MT
Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer	02/06	CI
Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as A First-Line Treatment for Upper GI Cancers	01/06	CI
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival	31/05	RE
Gilead Sciences Says Phase 3 Study Shows Trodelvy Cut Risk of Death by 16% in Non-Small Cell Lung Cancer Patients	31/05	MT
Disaster averted	31/05
Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study	31/05	CI
Gilead Sciences Says Phase 3 Trial in Urothelial Cancer Misses Primary Target	31/05	MT

Chart Gilead Sciences, Inc.

Duration

Period

More charts

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

64.27 USD

Average target price

82.7 USD

Spread / Average Target

+28.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GILEAD SCIENCES, INC.	-20.87%	80.07B
ELI LILLY AND COMPANY	+51.94%	797B
NOVO NORDISK A/S	+40.60%	628B
JOHNSON & JOHNSON	-6.69%	351B
MERCK & CO., INC.	+17.15%	323B
ABBVIE INC.	+11.02%	300B
ASTRAZENECA PLC	+17.13%	244B
ROCHE HOLDING AG	+0.98%	223B
AMGEN INC.	+6.09%	163B
PFIZER, INC.	-5.54%	153B

Other Pharmaceuticals

Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

EU regulator mandates label updates on CAR-T cancer therapies

Stocks mentioned in the article

EPS Revisions